Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation study of human umbilical cord mesenchymal stem cell injection for moderate to severe acute respiratory distress syndrome
CTR20250095Phase 2Active
- Sponsor
- Tuohua Biotech
- Start
- Apr 2025
- Countries
- 1
01
Overview
A Phase 2 trial of human umbilical cord mesenchymal stem cell in acute respiratory distress syndrome (ARDS), sponsored by Tuohua Biotech. Started Apr 2025; status: active.
02
Drugs
human umbilical cord mesenchymal stem cell
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on CTR20250095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250095.